XYRA Announces Issuance of US Patent to Reduce the Risk of Heart Failure or Strokes by Reducing the Number and Duration of Atrial Fibrillations

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

XYRA-Announcement

More Like This

PR Newswire associated0

XYRA Announces the Issuance of a Fifth New US Patent in a Series of Patents Which Protect the Use of Budiodarone in the Management of Atrial Fibrillation till after 2040

PR Newswire associated0

XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation

PR Newswire associated0

XYRA Announces FDA Label Guidance for Managing Atrial Fibrillation with Budiodarone and Wearable Monitoring Devices

PR Newswire associated0

CardiaCare Completes Seed Extension Raise to Support Clinical Pilot Studies

PR Newswire associated0

Volta Medical's RESTART Trial Shows Promising Findings for AI Solutions in Recurrent Atrial Fibrillation

PR Newswire associated0

Former Lions and Wales Rugby Captain Alun Wyn Jones partners with AliveCor to launch 'Let's Talk Rhythm' campaign to raise awareness of atrial fibrillation

AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation

PR Newswire associated0

AuriGen Medical Pioneers Next-Generation Atrial Fibrillation Technology with First-in-Human Success